IL239778A0 - Controlled release formulations of lorazepam - Google Patents

Controlled release formulations of lorazepam

Info

Publication number
IL239778A0
IL239778A0 IL239778A IL23977815A IL239778A0 IL 239778 A0 IL239778 A0 IL 239778A0 IL 239778 A IL239778 A IL 239778A IL 23977815 A IL23977815 A IL 23977815A IL 239778 A0 IL239778 A0 IL 239778A0
Authority
IL
Israel
Prior art keywords
lorazepam
controlled release
release formulations
formulations
controlled
Prior art date
Application number
IL239778A
Other languages
Hebrew (he)
Original Assignee
Edgemont Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL239778(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Edgemont Pharmaceuticals Llc filed Critical Edgemont Pharmaceuticals Llc
Publication of IL239778A0 publication Critical patent/IL239778A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Chemistry (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
IL239778A 2013-01-09 2015-07-05 Controlled release formulations of lorazepam IL239778A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361750792P 2013-01-09 2013-01-09
US201361762836P 2013-02-08 2013-02-08
PCT/US2014/010863 WO2014110248A1 (en) 2013-01-09 2014-01-09 Controlled release formulations of lorazepam

Publications (1)

Publication Number Publication Date
IL239778A0 true IL239778A0 (en) 2015-08-31

Family

ID=50030512

Family Applications (1)

Application Number Title Priority Date Filing Date
IL239778A IL239778A0 (en) 2013-01-09 2015-07-05 Controlled release formulations of lorazepam

Country Status (16)

Country Link
EP (1) EP2943186A1 (en)
JP (1) JP2016504391A (en)
KR (1) KR20150127037A (en)
CN (1) CN105188682A (en)
AU (1) AU2014205356A1 (en)
BR (1) BR112015016322A8 (en)
CA (1) CA2897313A1 (en)
CL (1) CL2015001921A1 (en)
HK (1) HK1213803A1 (en)
IL (1) IL239778A0 (en)
MX (1) MX2015008757A (en)
PE (1) PE20151431A1 (en)
PH (1) PH12015501533A1 (en)
RU (1) RU2015128914A (en)
SG (1) SG11201505352RA (en)
WO (1) WO2014110248A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019089330A1 (en) 2017-11-01 2019-05-09 Edgemont Pharmceuticals, Llc Trust Alcohol-resistant oral pharmaceutical compositions of lorazepam

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL298071A (en) 1963-06-04
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3786813A (en) 1972-12-27 1974-01-22 Alza Corp Drug delivery device with self actuated mechanism for retaining device in selected area
US4361545A (en) 1979-05-21 1982-11-30 Rowell Laboratories, Inc. Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion
KR850700212A (en) * 1984-03-21 1985-12-26 죠지 드모트 Sustained Release Pharmaceutical Wexel
US4624847A (en) 1985-04-22 1986-11-25 Alza Corporation Drug delivery device for programmed delivery of beneficial drug
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
US5945125A (en) 1995-02-28 1999-08-31 Temple University Controlled release tablet
CO5140079A1 (en) * 1998-10-14 2002-03-22 Novartis Ag PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT
WO2002045695A2 (en) 2000-12-05 2002-06-13 Alexander Macgregor Hydrostatic delivery system for controlled delivery of agent
IL159715A0 (en) 2001-07-10 2004-06-20 Teva Pharma Drug delivery system for zero order, zero order-biphasic, ascending or descending drug delivery
US6703045B2 (en) 2001-08-21 2004-03-09 Council Of Scientific & Industrial Research Composition and method for maintaining blood glucose level
BR0302017B1 (en) * 2003-06-02 2014-10-29 Ems Sigma Pharma Ltda Sublingual pharmaceutical composition based on a benzodiazepine central receptor agonist
KR100822519B1 (en) * 2005-02-15 2008-04-16 주식회사종근당 Single Matrix Tablets Controlled in the Gastrointestinal tract

Also Published As

Publication number Publication date
BR112015016322A2 (en) 2017-07-11
EP2943186A1 (en) 2015-11-18
JP2016504391A (en) 2016-02-12
SG11201505352RA (en) 2015-08-28
CA2897313A1 (en) 2014-07-17
PE20151431A1 (en) 2015-09-23
PH12015501533A1 (en) 2015-10-05
CN105188682A (en) 2015-12-23
KR20150127037A (en) 2015-11-16
BR112015016322A8 (en) 2018-01-23
HK1213803A1 (en) 2016-07-15
CL2015001921A1 (en) 2015-12-18
MX2015008757A (en) 2016-02-05
WO2014110248A1 (en) 2014-07-17
AU2014205356A1 (en) 2015-07-30
RU2015128914A (en) 2017-02-14

Similar Documents

Publication Publication Date Title
IL287516A (en) Therapeutic uses of empagliflozin
IL280485A (en) Modified release formulations of pridopidine
EP2991639A4 (en) Controlled release pharmaceutical formulations
IL241101B (en) Therapeutic uses of empagliflozin
IL241102A0 (en) Therapeutic uses of empagliflozin
IL245855A0 (en) Oral formulations of pyrrolydine derivatives
PL2981271T3 (en) Therapeutic uses of empagliflozin
ZA201604502B (en) Use of benzimidazole-proline derivatives
ZA201505830B (en) Formulations of organc compounds
ZA201508228B (en) Modified release formulation
EP2988595A4 (en) Gel formulations for extended release of volatile compounds
PL3049378T3 (en) Preparation of radioiodinated 3-fluoropropyl-nor-beta-cit
ZA201505082B (en) Sustained release formulations of lorazepam
IL239778A0 (en) Controlled release formulations of lorazepam
IL244725A0 (en) The continuous long-term controlled release of telomerase inhibitors
PL3071575T3 (en) Preparation of normorphinans